Charles River Labs Intl Logo
US1598641074
939391
CRL

Charles River Labs Intl

Loading quotes...

Forecast

The analysts' average price target is €275.55 (-13.03%). The median is €291.32 (-8.06%).

Buy
  27
Hold
  10
Sell
  0

Historical dividends Dividends

All dividend metrics All metrics
In 1996, Charles River Labs Intl has already paid €0.40 in dividends. The last payout was in December 1996.

Financials

In the last quarter, Charles River Labs Intl had revenue of €881.28m and net profit of -€1.3m
(EUR) June 2026
YoY
Revenue 881.28m 0.06%
Gross profit 318.93m 4.68%
Net profit -1.3m 102.91%
EBITDA 132.36m 29.78%

Fundamentals

Metric Value
Market capitalization
€14.87bn
Number of shares
48.17m
52-week high/low
€313.84 - €130.65
Dividends No
Beta
1.40
P/E ratio
-71.36
PEG ratio
0.74
P/B ratio
5.90
P/S ratio
4.16

Company profile

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Name
Charles River Labs Intl
CEO
Birgit Girshick
Headquarters Wilmington, ma
USA
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
23/06/2000
Employees 19,000

Ticker symbols

Exchange Symbol
NYSE
CRL
Frankfurt
RV6.F
Düsseldorf
RV6.DU
SIX
RV6.SW
München
RV6.MU
🍪

Parqet  uses cookies. Learn more